CG Invites Q1 2026: Revenue Up but Operating Loss Widens, Key License Terminated
Consolidated Q1 2026 revenue increased 39% YoY to 4.29 billion won, but operating loss expanded to 6.10 billion won (from 5.18 billion won).
Key pipeline CG-806 (blood cancer) license-out agreement terminated on April 30, 2026 due to licensee merger.
Domestic sales contract for Achelex with Dong-A ST also terminated on April 30, 2026.
Debt ratio rose to 92.18% (from 88.84% at year-end 2025); derivative financial liabilities of 25.5 billion won from redeemable convertible preferred shares.
Ongoing lawsuits: Cho Joong-myung ($100M), Park Pil-joon (5.54 billion won), Bellevue Capital (10.54 billion won) represent significant contingent liabilities.
Cash and cash equivalents decreased to 8.98 billion won (from 11.58 billion); R&D expenses 0.94 billion won (21.8% of revenue).
Consolidated net loss attributable to parent 4.47 billion won, basic EPS -59 won.